Trends in Antibody Titers after SARS-CoV-2 Vaccination—Insights from Self-Paid Tests at a General Internal Medicine Clinic
Abstract
:1. Introduction
2. Materials and Methods
2.1. Serology Assays
2.2. Statistical Analysis
3. Results
4. Discussion
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Conflicts of Interest
References
- Pilz, S.; Ioannidis, J.P.A. Does natural and hybrid immunity obviate the need for frequent vaccine boosters against SARS-CoV-2 in the endemic phase? Eur. J. Clin. Investig. 2023, 53, e13906. [Google Scholar] [CrossRef]
- Available online: https://www.kantei.go.jp/jp/headline/kansensho/vaccine_supply.html (accessed on 26 February 2023).
- Available online: https://www.kansensho.or.jp/uploads/files/guidelines/2112_covid-19_4.pdf (accessed on 26 February 2023).
- The Lancet Infectious Diseases. Why hybrid immunity is so triggering. Lancet Infect. Dis. 2022, 22, 1649. [Google Scholar] [CrossRef] [PubMed]
- Almadhi, M.; Alsayyad, A.S.; Conroy, R.; Atkin, S.; Al Awadhi, A.; Al-Tawfiq, J.A.; AlQahtani, M. Epidemiological assessment of SARS-CoV-2 reinfection. Int. J. Infect. Dis. 2022, 123, 9–16. [Google Scholar] [CrossRef] [PubMed]
- Nordström, P.; Ballin, M.; Nordström, A. Risk of SARS-CoV-2 reinfection and COVID-19 hospitalisation in individuals with natural and hybrid immunity: A retrospective, total population cohort study in Sweden. Lancet Infect. Dis. 2022, 22, 781–790. [Google Scholar] [CrossRef] [PubMed]
- Robertson, L.J.; Price, R.; Moore, J.S.; Curry, G.; Farnan, J.; Black, A.; Blighe, K.; Nesbit, M.A.; McLaughlin, J.A.D.; Moore, T. IgG antibody production and persistence to 6 months following SARS-CoV-2 vaccination: A Northern Ireland observational study. Vaccine 2022, 40, 2535–2539. [Google Scholar] [CrossRef]
- Sarrigeorgiou, I.; Moschandreou, D.; Dimitriadis, A.; Tsinti, G.; Sotiropoulou, E.; Ntoukaki, E.; Sotiropoulou, E.; Ntoukaki, E.; Eliadis, P.; Backovic, M.; et al. Combined monitoring of IgG and IgA anti-Spike and anti-Receptor binding domain long term responses following BNT162b2 mRNA vaccination in Greek healthcare workers. PLoS ONE 2022, 17, e0277827. [Google Scholar] [CrossRef]
- Desmecht, S.; Tashkeev, A.; El Moussaoui, M.; Marechal, N.; Perée, H.; Tokunaga, Y.; Fombellida-Lopez, C.; Polese, B.; Legrand, C.; Wery, M.; et al. Kinetics and Persistence of the Cellular and Humoral Immune Responses to BNT162b2 mRNA Vaccine in SARS-CoV-2-Naive and -Experienced Subjects: Impact of Booster Dose and Breakthrough Infections. Front. Immunol. 2022, 13, 863554. [Google Scholar] [CrossRef]
- Walls, A.C.; Sprouse, K.R.; Bowen, J.E.; Joshi, A.; Franko, N.; Navarro, M.J.; Stewart, C.; Cameroni, E.; McCallum, M.; Goecker, E.A.; et al. SARS-CoV-2 breakthrough infections elicit potent, broad, and durable neutralizing antibody responses. Cell 2022, 185, 872–880.e3. [Google Scholar] [CrossRef] [PubMed]
- Kusunoki, H.; Ohkusa, M.; Iida, R.; Saito, A.; Kawahara, M.; Ekawa, K.; Kato, N.; Yamasaki, K.; Motone, M.; Shimizu, H. Longitudinal Changes in IgG-Type SARS-CoV-2 Antibody Titers after COVID-19 Vaccination and a Prominent Increase in Antibody Titers When Infected after Vaccination. Vaccines 2023, 11, 860. [Google Scholar] [CrossRef]
- Kared, H.; Wolf, A.S.; Alirezaylavasani, A.; Ravussin, A.; Solum, G.; Tran, T.T.; Lund-Johansen, F.; Vaage, J.T.; Nissen-Meyer, L.S.; Nygaard, U.C.; et al. Immune responses in Omicron SARS-CoV-2 breakthrough infection in vaccinated adults. Nat. Commun. 2022, 13, 4165. [Google Scholar] [CrossRef]
- Matsuura, T.; Fukushima, W.; Nakagama, Y.; Kido, Y.; Kase, T.; Kondo, K.; Kaku, N.; Matusmoto, K.; Suita, A.; Komiya, E.; et al. Kinetics of anti-SARS-CoV-2 antibody titer in healthy adults up to 6 months after BNT162b2 vaccination measured by two immunoassays: A prospective cohort study in Japan. Vaccine 2022, 40, 5631–5640. [Google Scholar] [CrossRef]
- Willyard, C. How quickly does COVID immunity fade? What scientists know. Nature 2023, 614, 395–396. [Google Scholar] [CrossRef]
- Uwamino, Y.; Kurafuji, T.; Sato, Y.; Tomita, Y.; Shibata, A.; Tanabe, A.; Yatabe, Y.; Noguchi, M.; Arai, T.; Ohno, A.; et al. Young age, female sex, and presence of systemic adverse reactions are associated with high post-vaccination antibody titer after two doses of BNT162b2 mRNA SARS-CoV-2 vaccination: An observational study of 646 Japanese healthcare workers and university staff. Vaccine 2022, 40, 1019–1025. [Google Scholar] [CrossRef]
- Nomura, Y.; Sawahata, M.; Nakamura, Y.; Kurihara, M.; Koike, R.; Katsube, O.; Hagiwara, K.; Niho, S.; Masuda, N.; Tanaka, T.; et al. Age and Smoking Predict Antibody Titres at 3 Months after the Second Dose of the BNT162b2 COVID-19 Vaccine. Vaccines 2021, 9, 1042. [Google Scholar] [CrossRef]
- Müller, L.; Andrée, M.; Moskorz, W.; Drexler, I.; Walotka, L.; Grothmann, R.; Ptok, J.; Hillebrandt, J.; Ritchie, A.; Rabl, D.; et al. Age-dependent Immune Response to the Biontech/Pfizer BNT162b2 Coronavirus Disease 2019 Vaccination. Clin. Infect. Dis. 2021, 73, 2065–2072. [Google Scholar] [CrossRef]
- Terpos, E.; Trougakos, I.P.; Apostolakou, F.; Charitaki, I.; Sklirou, A.D.; Mavrianou, N.; Papanagnou, E.-D.; Liacos, C.-I.; Gumeni, S.; Rentziou, G.; et al. Age-dependent and gender-dependent antibody responses against SARS-CoV-2 in health workers and octogenarians after vaccination with the BNT162b2 mRNA vaccine. Am. J. Hematol. 2021, 96, E257–E259. [Google Scholar] [CrossRef]
- Canetti, M.; Barda, N.; Gilboa, M.; Indenbaum, V.; Asraf, K.; Gonen, T.; Weiss-Ottolenghi, Y.; Amit, S.; Doolman, R.; Mendelson, E.; et al. Six-Month Follow-up after a Fourth BNT162b2 Vaccine Dose. N. Engl. J. Med. 2022, 387, 2092–2094. [Google Scholar] [CrossRef]
- Malato, J.; Ribeiro, R.M.; Fernandes, E.; Leite, P.P.; Casaca, P.; Antunes, C.; Fonseca, V.R.; Gomes, M.C.; Graca, L. Stability of hybrid versus vaccine immunity against BA.5 infection over 8 months. Lancet Infect. Dis. 2023, 23, 148–150. [Google Scholar] [CrossRef]
- Marking, U.; Bladh, O.; Havervall, S.; Svensson, J.; Greilert-Norin, N.; Aguilera, K.; Kihlgren, M.; Salomonsson, A.-C.; Mansson, M.; Gallini, R.; et al. 7-month duration of SARS-CoV-2 mucosal immunoglobulin—A responses and protection. Lancet Infect. Dis. 2023, 23, 150–152. [Google Scholar] [CrossRef]
- Bobrovitz, N.; Ware, H.; Ma, X.; Li, Z.; Hosseini, R.; Cao, C.; Selemon, A.; Whelan, M.; Premji, Z.; Issa, H.; et al. Protective effectiveness of previous SARS-CoV-2 infection and hybrid immunity against the omicron variant and severe disease: A systematic review and meta-regression. Lancet Infect. Dis. 2023. [Google Scholar] [CrossRef]
- Hall, V.; Foulkes, S.; Insalata, F.; Kirwan, P.; Saei, A.; Atti, A.; Wellington, E.; Khawam, J.; Munro, K.; Cole, M.; et al. Protection against SARS-CoV-2 after COVID-19 Vaccination and Previous Infection. N. Engl. J. Med. 2022, 386, 1207–1220. [Google Scholar] [CrossRef]
- Sidik, S.M. COVID vaccine plus infection can lead to months of immunity. Nature 2022. [Google Scholar] [CrossRef]
- Dan, J.M.; Mateus, J.; Kato, Y.; Hastie, K.M.; Yu, E.D.; Faliti, C.; Grifoni, A.; Ramirez, S.I.; Haupt, S.; Frazier, A.; et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science 2021, 371, eabf4063. [Google Scholar] [CrossRef]
- Crotty, S. Hybrid immunity: COVID-19 vaccine responses provide insights into how the immune system perceives threats. Science 2021, 372, 1392–1393. [Google Scholar] [CrossRef]
- Chemaitelly, H.; Nagelkerke, N.; Ayoub, H.H.; Coyle, P.; Tang, P.; Yassine, H.M.; Al-Khatib, H.A.; Smatti, M.K.; Hasan, M.R.; Al-Kanaani, Z.; et al. Duration of immune protection of SARS-CoV-2 natural infection against reinfection. J. Travel Med. 2022, 29, taac109. [Google Scholar] [CrossRef]
Total Participants | Participants up to the Second Dose | Participants up to the Third Dose | Participants up to the Fourth Dose | |
---|---|---|---|---|
Total | 133 | 127 | 97 | 53 |
Male, n (%) | 49 (36.8) | 48 (37.8) | 35 (36.1) | 21 (39.6) |
Female, n (%) | 84 (63.2) | 79 (62.2) | 62 (63.9) | 32 (60.4) |
Mean age Median age | 65.7 ± 19.1 70 | 66.4 ± 18.7 70 | 70.2 ± 16.1 72 | 74.3 ± 12.5 75 |
Type of vaccine | BNT162b2 (BioNTech and Pfizer), n (%) | 115 (90.5) | 65 (67.0) | 39 (73.6) |
mRNA-1273 (Moderna and Takeda), n (%) | 1 (0.8) | 30 (30.9) | 11 (20.7) | |
Unknown, n (%) | 11 (8.7) | 2 (2.1) | 3 (5.7) | |
No vaccination history, n (%) | 6 (4.5) |
Analyzed Participants up to the Second Dose | Analyzed Participants up to the Third Dose | ||
---|---|---|---|
Total | 86 | 31 | |
Male, n (%) | 36 (41.9) | 11 (35.5) | |
Female, n (%) | 50 (58.1) | 20 (64.5) | |
Mean age | 67.3 ± 17.2 | 69.9 ± 16.8 | |
Median age | 68.5 | 72 | |
Type of vaccine | BNT162b2 (BioNTech and Pfizer), n (%) | 86 (100) | 27 (87.1) |
mRNA-1273 (Moderna and Takeda), n (%) | 0 (0) | 4 (12.9) | |
Median antibody titer (U/mL) | 1185 | 18,300 | |
Median log (antibody titer) | 7.1 | 9.8 | |
Mean number of days between the vaccination and the measurement day (Mean ± standard deviation) | 14.9 ± 2.5 | 15.6 ± 2.6 |
A. Participants Who Became Infected after the Second Dose of Vaccine. | |||||||
Case | 1st Vaccination Date | Date of Infection | Days from 2nd Vaccination to Infection | Post-Infection Antibody Test Date | Post-Infection Antibody Titer (U/mL) | Number of Days from Infection to Antibody Titer Measurement | 3rd Vaccination Date |
2nd Vaccination Date | |||||||
44M | 11 August 2021 | 3 March 2022 | 183 | 9 April 2022 | 113,000 | 37 | |
1 September 2021 | |||||||
51F | unknown | 15 January 2022 | 4 March 2022 | 26,600 | 48 | 9 March 2022 | |
unknown | |||||||
B. Participants who became infected after the third dose of vaccine | |||||||
Case | 1st Vaccination Date | Date of Infection | Days from 3rd Vaccination to Infection | Post-Infection Antibody Test Date | Post-Infection Antibody Titer (U/mL) | Number of Days from Infection to Antibody Titer Measurement | 4th Vaccination Date |
2nd Vaccination Date | |||||||
3rd Vaccination Date | |||||||
65F | 22 June 2021 | 29 March 2022 | 36 | 12 April 2022 | 20,500 | 14 | 3 August 2022 |
13 July 2021 | |||||||
21 February 2022 | |||||||
75F | 23 June 2021 | 14 July 2022 | 118 | 25 July 2022 | 12,200 | 11 | |
14 July 2021 | |||||||
18 March 2022 | |||||||
57F | unknown | 18 August 2022 | 160 | 13 September 2022 | 59,600 | 26 | |
unknown | |||||||
11 March 2022 | |||||||
75M | 26 June 2021 | 8 August 2022 | 156 | 26 August 2022 | 41,000 | 18 | 26 August 2022 |
17 July 2021 | |||||||
5 March 2022 | |||||||
71F | 10 July 2021 | 10 August 2022 | 153 | 26 August 2022 | 9840 | 16 | 26 August 2022 |
31 July 2021 | |||||||
10 March 2022 | |||||||
71F | unknown | 11 March 2022 | 31 | 25 April 2022 | 63,400 | 45 | 3 August 2022 |
unknown | |||||||
8 February 2022 | |||||||
C. Participants who became infected after the fourth dose of vaccine | |||||||
Case | 1st Vaccination Date | Date of Infection | Days from 4th Vaccination to Infection | Post-Infection Antibody Test Date | Post-Infection Antibody Titer (U/mL) | Number of Days from Infection to Antibody Titer Measurement | |
2nd Vaccination Date | |||||||
3rd Vaccination Date | |||||||
4th Vaccination Date | |||||||
85F | unknown | 21 August 2022 | 44 | 13 September 2022 | 122,000 | 23 | |
unknown | |||||||
8 February 2022 | |||||||
8 July 2022 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Kusunoki, H.; Ekawa, K.; Ekawa, M.; Kato, N.; Yamasaki, K.; Motone, M.; Shimizu, H. Trends in Antibody Titers after SARS-CoV-2 Vaccination—Insights from Self-Paid Tests at a General Internal Medicine Clinic. Medicines 2023, 10, 27. https://doi.org/10.3390/medicines10040027
Kusunoki H, Ekawa K, Ekawa M, Kato N, Yamasaki K, Motone M, Shimizu H. Trends in Antibody Titers after SARS-CoV-2 Vaccination—Insights from Self-Paid Tests at a General Internal Medicine Clinic. Medicines. 2023; 10(4):27. https://doi.org/10.3390/medicines10040027
Chicago/Turabian StyleKusunoki, Hiroshi, Kazumi Ekawa, Masakazu Ekawa, Nozomi Kato, Keita Yamasaki, Masaharu Motone, and Hideo Shimizu. 2023. "Trends in Antibody Titers after SARS-CoV-2 Vaccination—Insights from Self-Paid Tests at a General Internal Medicine Clinic" Medicines 10, no. 4: 27. https://doi.org/10.3390/medicines10040027